1AZ2

CITRATE BOUND, C298A/W219Y MUTANT HUMAN ALDOSE REDUCTASE

1AZ2 の概要

• エントリーDOI: 10.2210/pdb1az2/pdb
• 分子名称: ALDOSE REDUCTASE, NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, CITRIC ACID (3 entities in total)
• 機能のキーワード: oxidoreductase, aldo-keto reductase, inhibitor binding
• 由来する生物種: Homo sapiens (human)
• 細胞内の位置: Cytoplasm: P15121
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 36647.58

構造登録者

Harrison, D.H.,Bohren, K.M.,Ringe, D.,Petsko, G.A.,Gabbay, K.H. (登録日: 1997-11-24, 公開日: 1998-03-18, 最終更新日: 2024-05-22)

主引用文献

Harrison, D.H.,Bohren, K.M.,Petsko, G.A.,Ringe, D.,Gabbay, K.H.
The alrestatin double-decker: binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant.
Biochemistry, 36:16134-16140, 1997

PubMed Abstract: It is generally expected that only one inhibitor molecule will bind to an enzyme active site. In fact, specific drug design theories depend upon this assumption. Here, we report the binding of two molecules of an inhibitor to the same active site which we observed in the 1.8 A resolution structure of the drug Alrestatin bound to a mutant of human aldose reductase. The two molecules of Alrestatin bind to the active site in a stacked arrangement (a double-decker). This stack positions the carboxylic acid of one drug molecule near the NADP+ cofactor at a previously determined anion binding site and the carboxylic acid of the second drug molecule near the carboxy-terminal tail of the enzyme. We propose that interactions of inhibitors with the carboxy-terminal loop of aldose reductase are critical for the development of inhibitors that are able to discriminate between aldose reductase and other members of the aldo-keto reductase superfamily. This finding suggests a new direction for the introduction of specificity to aldose reductase-targeted drugs.

PubMed: 9405046
DOI: 10.1021/bi9717136

実験手法

X-RAY DIFFRACTION (2.9 Å)